Results 281 to 290 of about 669,728 (307)

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

New England Journal of Medicine, 1987
W M Linehan
exaly  

Interleukin-5

2006
openaire   +1 more source

Interleukin-5

2011
openaire   +1 more source

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2015
Philip J Mease, Bruce W Kirkham, Arthur Kavanaugh   +2 more
exaly  

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Lancet, The, 2013
Antoinette Moran, Linda A Dimeglio, Carla J Greenbaum   +2 more
exaly  

Nasal polyposis: eosinophils and interleukin‐5

Allergy, 1999
M F, Kramer, G, Rasp
openaire   +2 more sources

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

New England Journal of Medicine, 2012
Claus Otto Carl Zachariae
exaly  

Interleukin 5

2000
openaire   +1 more source

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Lancet, The, 2017
Geert D'Haens, Julian Panes, Arthur Kaser   +2 more
exaly  

[Interleukin-5 receptor].

Nihon rinsho. Japanese journal of clinical medicine, 1997
N, Ogata, K, Takatsu
openaire   +1 more source